CBLIF: A Potential Drug Target for Cancer and Immune-related Diseases

Target Name: CBLIF

NCBI ID: G2694

CBLIF

CBLIF: A Potential Drug Target for Cancer and Immune-related Diseases

CBLIF (Complementum Biosciences Library Interface), also known as INF (Interactive Name Entity Function), is a protein that is expressed in various tissues and cells in the human body. It is a key regulator of the immune system and has been implicated in a number of diseases, including cancer. As a drug target, CBLIF is a potential target for new therapies in various diseases.

CBLIF is a protein that is composed of two heavy chains and two light chains. The heavy chains contain a variable region and a constant region, while the light chains contain a variable region and a constant region. The variable regions contain the majority of the protein's functional domain, including the region that interacts with other proteins to regulate the immune response.

One of the unique features of CBLIF is its ability to interact with other proteins. This interaction is critical for its function as a regulator of the immune system. CBLIF has been shown to interact with a number of different proteins, including the B cell receptor ( BCR), which is a key regulator of the immune response.

CBLIF has also been shown to interact with the protein PDGF-BB, which is a growth factor that plays a role in the development and maintenance of tissues. The interaction between CBLIF and PDGF-BB has been shown to promote the growth and survival of cancer cells.

Another potential drug target for CBLIF is its role in the regulation of cell death. Studies have shown that CBLIF has been shown to interact with the protein p53, which is a tumor suppressor protein that is responsible for preventing the uncontrolled growth and division of cells. The The interaction between CBLIF and p53 has been shown to promote the growth and survival of cancer cells.

CBLIF has also been shown to interact with the protein NF-kappa-B, which is a transcription factor that plays a role in the regulation of inflammation and immune responses. The interaction between CBLIF and NF-kappa-B has been shown to promote the production of pro- inflammatory cytokines, which can contribute to the development and progression of inflammatory diseases.

In addition to its role in the regulation of the immune system, CBLIF has also been shown to play a role in the regulation of cell signaling pathways. For example, it has been shown to interact with the protein Src, which is a receptor tyrosine kinase that is involved in the regulation of cell signaling pathways. The interaction between CBLIF and Src has been shown to promote the formation of protein-protein interaction networks and the regulation of cellular signaling pathways.

Despite its potential as a drug target, CBLIF is still an relatively unexplored protein. There are currently no known drugs that are specifically designed to target CBLIF. However, this is likely to change as new research into the biology and function of CBLIF continues.

In conclusion, CBLIF is a protein that has been shown to play a number of important roles in the regulation of the immune system and cell signaling pathways. Its unique ability to interact with other proteins makes it an attractive target for new therapies in a variety of diseases. Further research is needed to fully understand the biology and function of CBLIF and to develop new treatments.

Protein Name: Cobalamin Binding Intrinsic Factor

Functions: Promotes absorption of the essential vitamin cobalamin (Cbl) in the ileum. After interaction with CUBN, the CBLIF-cobalamin complex is internalized via receptor-mediated endocytosis

The "CBLIF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CBLIF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets